title: Reduction of carcinomatosis risk using icodextrin as a carrier solution of intraperitoneal oxaliplatin chemotherapy.
abstract: There is no standard treatment in patients with high risk metachronous peritoneal carcinomatosis (PC) in colonic cancer, as perforated tumour or synchronous ovarian metastasis. Icodextrin 4% (ICDX), presently used to prevent postoperative abdominal adhesions, could inhibit the coactivation of the tumour cells and the microenvironment cells, associated with the development of PC. The aim of this study was to inhibit the formation of the PC in a murine model mimicking surgical situation using ICDX and intraperitoneal (IP) prophylactic chemotherapy. We created a model of growing PC in mice using cells of murine colonic cancer CT26. Cells and treatments were injected simultaneously. Five groups were created: CT26 (control group), CT26 + ICDX (ICDX group), CT26 + chemotherapy (oxaliplatin and 5FU) (chemo group), CT26 + chemotherapy + ICDX (ICDX chemo group), ICDX (toxicity group). At day 15, PC was evaluated with rodents PCI. In the chemo group, PCI was significantly lower than in the control group (3.2 versus 8.4, p = 0.02). ICDX had a synergetic effect on PC with chemotherapy; indeed PCI in ICDX chemo group was lower than in chemo group (1.4 versus 3.2, p = 0.04). There was no morbidity linked to ICDX in toxicity group. Safety of ICDX needs to be verified, particularly on colonic anastomosis before ICDX associated to IP chemotherapy could be used as a preventive treatment of PC in high risk patients. This prophylactic treatment is easy to use and would be administrated at the end of a curative surgery for a colonic cancer.
authors.affiliation: Department of Oncologic & Digestive Surgery, Hospital Lariboisière - AP-HP, 2 rue Ambroise Paré, 75475 Paris Cedex 10, France; Université Paris Diderot, Sorbonne Paris Cité, CART, Carcinomatosis Angiogenesis Translational Research, INSERM U965, F-74575 Paris, France.
authors.forename: I
authors.initials: I
authors.lastname: Jouvin
authors.affiliation: Department of Oncologic & Digestive Surgery, Hospital Lariboisière - AP-HP, 2 rue Ambroise Paré, 75475 Paris Cedex 10, France; Université Paris Diderot, Sorbonne Paris Cité, CART, Carcinomatosis Angiogenesis Translational Research, INSERM U965, F-74575 Paris, France.
authors.forename: H
authors.initials: H
authors.lastname: Najah
authors.affiliation: Université Paris Diderot, Sorbonne Paris Cité, CART, Carcinomatosis Angiogenesis Translational Research, INSERM U965, F-74575 Paris, France.
authors.forename: C
authors.initials: C
authors.lastname: Pimpie
authors.affiliation: Université Paris Diderot, Sorbonne Paris Cité, CART, Carcinomatosis Angiogenesis Translational Research, INSERM U965, F-74575 Paris, France.
authors.forename: C
authors.initials: C
authors.lastname: Canet Jourdan
authors.affiliation: Department of Anatomopathology, Hôpital Lariboisière - AP-HP, 2 rue Ambroise Paré, 75475 Paris Cedex 10, France.
authors.forename: R
authors.initials: R
authors.lastname: Kaci
authors.affiliation: Université Paris Diderot, Sorbonne Paris Cité, CART, Carcinomatosis Angiogenesis Translational Research, INSERM U965, F-74575 Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Mirshahi
authors.affiliation: Department of Oncologic & Digestive Surgery, Hospital Lariboisière - AP-HP, 2 rue Ambroise Paré, 75475 Paris Cedex 10, France; Université Paris Diderot, Sorbonne Paris Cité, CART, Carcinomatosis Angiogenesis Translational Research, INSERM U965, F-74575 Paris, France.
authors.forename: C
authors.initials: C
authors.lastname: Eveno
authors.affiliation: Department of Oncologic & Digestive Surgery, Hospital Lariboisière - AP-HP, 2 rue Ambroise Paré, 75475 Paris Cedex 10, France; Université Paris Diderot, Sorbonne Paris Cité, CART, Carcinomatosis Angiogenesis Translational Research, INSERM U965, F-74575 Paris, France. Electronic address: marc.pocard@gmail.com.
authors.forename: M
authors.initials: M
authors.lastname: Pocard
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000494:pharmacology*; D002277:Carcinoma / Q000188:drug therapy* / Q000556:secondary; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D015314:Dialysis Solutions / Q000494:pharmacology* / Q000627:therapeutic use; D004195:Disease Models, Animal; D005472:Fluorouracil / Q000008:administration & dosage / Q000494:pharmacology; D005936:Glucans / Q000494:pharmacology* / Q000627:therapeutic use; D005947:Glucose / Q000494:pharmacology* / Q000627:therapeutic use; D000077607:Icodextrin; D007263:Infusions, Parenteral; D051379:Mice; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000494:pharmacology; D000077150:Oxaliplatin; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary
chemical_list: D015314:Dialysis Solutions; D005936:Glucans; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000077607:Icodextrin; D005947:Glucose; D005472:Fluorouracil
keywords: Carcinomatosis; Colon cancer; Experimental study; Prophylactic treatment